Stockscreener 앱 받기
4.05
1.94%
-0.08
전일 마감가:
$4.13
열려 있는:
$4.08
하루 거래량:
372.43K
Relative Volume:
0.45
시가총액:
$78.33M
수익:
$1.54M
순이익/손실:
$-84.53M
주가수익비율:
-0.6965
EPS:
-5.8145
순현금흐름:
$-73.65M
1주 성능:
-10.40%
1개월 성능:
-47.67%
6개월 성능:
-60.37%
1년 성능:
-76.70%
1일 변동 폭
$3.93
$4.08
1주일 범위
$3.93
$4.68
52주 변동 폭
$3.93
$18.11
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, MRNA, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
4.05 | 78.33M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-29 | 개시 | Guggenheim | Buy |
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026 - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
A throat cancer trial doses its first patient as Corbus (CRBP) reports CRB-701 response data. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38 - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RA Capital Management Acquires 1,914,788 Shares of Corbus Pharmaceuticals (CRBP) - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Four parties report the same Corbus (CRBP) stake, held directly by one fund. - stocktitan.net
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
EBITDA of Corbus Pharmaceuticals Holdings Inc – HAN:3371 - TradingView
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - finance.yahoo.com
About 14,000 U.S. patients may qualify yearly for another throat cancer treatment. Corbus doses its first trial patient. - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why Is Corbus Pharmaceuticals (NASDAQ:CRBP) Moving Into Focus? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) the Cannabis Stocks Stock Everyone's About to Talk About? - Kalkine Media
(CRBP) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
What Did CANYON Study Data Show for Corbus Pharmaceuticals (NASDAQ:CRBP)? - Kalkine Media
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals stock holds at USD 1.56 - AD HOC NEWS
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings (Nasdaq:CRBP)Stock Analysis - Simply Wall Street
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
CRBP - Finviz
Corbus Pharmaceuticals Holdings Inc. Stock Rallies 4.9%, Outperforms Peers - webull.com
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss TherapySlideshow (NASDAQ:CRBP) 2026-09-17 - Seeking Alpha
Corbus Pharmaceuticals Holdings Inc. Stock Slides 14.4%, Underperforms Peers - webull.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals stock rises on obesity drug trial data - Investing.com
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corbus Pharmaceuticals Holdings Inc 주식 (CRBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saxena Nishant C | Chief Business Officer |
Aug 11 '26 |
Buy |
9.63 |
2,600 |
25,036 |
77,900 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
17,000 |
171,396 |
0 |
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
| Stifel, Nicolaus & Company, In | Officer |
Aug 07 '26 |
Proposed Sale |
10.08 |
12,000 |
120,971 |
0 |
| Smethurst Dominic | Officer |
Jul 27 '26 |
Proposed Sale |
9.20 |
23,025 |
211,818 |
0 |
| Kung Winston | Director |
Jun 10 '26 |
Sale |
7.91 |
2,026 |
16,033 |
12,140 |
| Altmeyer Anne | Director |
Jun 10 '26 |
Sale |
7.91 |
2,412 |
19,088 |
7,579 |
| Jenkins John Kenneth | Director |
Jun 10 '26 |
Sale |
7.91 |
4,800 |
37,986 |
3,833 |
| Saxena Nishant C | Chief Business Officer |
Jun 03 '26 |
Buy |
7.58 |
9,000 |
68,220 |
75,300 |
3.09%
0.72%
자본화:
|
볼륨(24시간):